Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

676 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction.
Santhanakrishnan R, Chong JP, Ng TP, Ling LH, Sim D, Leong KT, Yeo PS, Ong HY, Jaufeerally F, Wong R, Chai P, Low AF, Richards AM, Lam CS. Santhanakrishnan R, et al. Eur J Heart Fail. 2012 Dec;14(12):1338-47. doi: 10.1093/eurjhf/hfs130. Epub 2012 Aug 5. Eur J Heart Fail. 2012. PMID: 22869458 Free article.
Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial.
Lam CS, Carson PE, Anand IS, Rector TS, Kuskowski M, Komajda M, McKelvie RS, McMurray JJ, Zile MR, Massie BM, Kitzman DW. Lam CS, et al. Circ Heart Fail. 2012 Sep 1;5(5):571-8. doi: 10.1161/CIRCHEARTFAILURE.112.970061. Epub 2012 Aug 10. Circ Heart Fail. 2012. PMID: 22887722 Free PMC article. Clinical Trial.
The Singapore Heart Failure Outcomes and Phenotypes (SHOP) study and Prospective Evaluation of Outcome in Patients with Heart Failure with Preserved Left Ventricular Ejection Fraction (PEOPLE) study: rationale and design.
Santhanakrishnan R, Ng TP, Cameron VA, Gamble GD, Ling LH, Sim D, Leong GK, Yeo PS, Ong HY, Jaufeerally F, Wong RC, Chai P, Low AF, Lund M, Devlin G, Troughton R, Richards AM, Doughty RN, Lam CS. Santhanakrishnan R, et al. J Card Fail. 2013 Mar;19(3):156-62. doi: 10.1016/j.cardfail.2013.01.007. J Card Fail. 2013. PMID: 23482075
Acute hemodynamic effects of riociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study.
Bonderman D, Pretsch I, Steringer-Mascherbauer R, Jansa P, Rosenkranz S, Tufaro C, Bojic A, Lam CSP, Frey R, Ochan Kilama M, Unger S, Roessig L, Lang IM. Bonderman D, et al. Among authors: lam csp. Chest. 2014 Nov;146(5):1274-1285. doi: 10.1378/chest.14-0106. Chest. 2014. PMID: 24991733 Free PMC article. Clinical Trial.
Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries.
Greene SJ, Shah AN, Butler J, Ambrosy AP, Anker SD, Chioncel O, Collins SP, Dinh W, Dunnmon PM, Fonarow GC, Lam CS, Mentz RJ, Pieske B, Roessig L, Rosano GM, Sato N, Vaduganathan M, Gheorghiade M. Greene SJ, et al. Am Heart J. 2014 Aug;168(2):142-9. doi: 10.1016/j.ahj.2014.05.009. Epub 2014 May 24. Am Heart J. 2014. PMID: 25066552 Free PMC article.
676 results